CD33 and acute myeloid leukemia: Therefore, the FDA has granted accelerated approval to gemtuzumab ozogamicin (GO), which is a humanized monoclonal antibody that binds with the IgV domain of CD33 for older patients with relapsed CD33-positive AML [7].